Vertex Pharmaceuticals reported that 10 of 12 type 1 diabetes patients treated with their investigational off-the-shelf stem cell therapy, zimislecel, maintained insulin independence for at least one year post-infusion. Presented at the ADA 2025 meeting and published in The New England Journal of Medicine, the therapy uses lab-grown insulin-producing islet cells derived from stem cells, representing a promising advance toward durable, cell-based treatments for diabetes without the need for injections.